Tom Collins is a freelance writer in South Florida who has written about medical topics from nasty infections to ethical dilemmas, runaway tumors to tornado-chasing doctors. He travels the globe gathering conference health news and lives in West Palm Beach.
News
‘Year of AML’ just the beginning, expert says
- Author:
- Thomas R. Collins
SAN FRANCISCO – New therapies for acute myeloid leukemia are finally being developed after a long stagnation.
News
Tailored approaches to relapsed/recalcitrant myeloma found within NCCN guidelines
- Author:
- Thomas R. Collins
SAN FRANCISCO – The approach to relapsed/refractory multiple myeloma (MM) has to be tailored patient by patient based on the biology of the...
News
Minimal residual disease measures not yet impactful for AML patients
- Author:
- Thomas R. Collins
Measuring MRD makes sense in AML patients in clinical trials, but does not add value in clinical practice.
News
ALL therapies grow, so do the complexities of choosing the order of treatments
- Author:
- Thomas R. Collins
The main challenge for the field is deciding when and how to use the increasing variety of ALL therapies.
News
High rate of cannabis use among cancer patients
- Author:
- Thomas R. Collins
Nearly a quarter of cancer patients used cannabis in the past year.
News
Primary care deficient in cancer survivor care
- Author:
- Thomas R. Collins
Primary care physicians falling short with cancer survivors.
News
No overall survival benefit from early SIRT for liver metastases from colorectal cancer
- Author:
- Thomas R. Collins
“Early use of SIRT in combination with first-line oxaliplatin-based chemotherapy cannot be recommended in unselected patients with metastatic...
News
ASCO issues new guideline on stage IV NSCLC
- Author:
- Thomas R. Collins
Use of checkpoint inhibitors recommended for some patients with non–small-cell lung cancer.
News
Study findings cast doubt on community-acquired pneumonia diagnostic practices
- Author:
- Thomas R. Collins
Practice changes may be necessary.
News
Obinutuzumab-CHOP not superior to rituximab-CHOP in new DLBCL
- Author:
- Thomas R. Collins
Two drug regimens for diffuse large B-cell lymphoma compared in a phase 3 trial.
News
Crizotinib shows responses in pediatric ALCL and IMT
- Author:
- Thomas R. Collins
Eighty percent of ALK-positive anaplastic large cell lymphoma patients in the high-dose group had a complete response, along with 83% given the...
News
Allele-matching in cord blood transplant yields better survival
- Author:
- Thomas R. Collins
Matching down to the allele level in umbilical cord blood transplantation between unrelated donors results in greater overall survival for those...
News
Blood markers can detect early pancreatic cancer
- Author:
- Thomas R. Collins
A test in development is recommended for those at high risk and those newly diagnosed with diabetes.
News
Midostaurin improves survival in new AML
- Author:
- Thomas R. Collins
Adding the multitargeted kinase inhibitor midostaurin to standard chemotherapy led to significantly longer overall and event-free survival...
News
Gilteritinib shows safety, efficacy in relapsed/refractory AML
- Author:
- Thomas R. Collins
Gilteritinib is attractive because it has in vitro activity against FLT3 internal tandem duplication mutations and tyrosine kinase domain...